Abstract
Fifty girls with Turner's Syndrome (67%-45X, 33% other karyotypes) aged 3.0 - 9.9 years treated with biosynthetic GH at dose of 20 or 40 IU/m body surface per week in 7 subcutaneous injections.
The patients were assigned into 25 pairs according to their chronological age (CA). degree of bone retardation (BA) as compared with their chronological age. average parental height and degree of growth deficiency of the child in terms of mean parental height. In each pair, doses of 20 IU/m /week (Group A) or 40 IU/m ./week (Group B) were randomly assigned.
Analysis of the first year of treatment was carried out on two age groups; 3.0-6.9 years (20 patients) and 7.0-9.9 years (30 patients).
We did not find significant differences among the children in Group A and B in the younger age category. We did not find any differences between Groups A and B in bone age advancement over the 1 year period of treatment regardless of the patient's age. We also did not observe any side-effects during treatment or differences in fasting glucose or insulin levels among Groups A and B.
We believe that doses of GH exceeding 20 IU/m, body surface per week should not be administered to TS patients under the age of 7 years.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wisniewski, A., Romer, T., Rymkiewicz-Kluczyska, B. et al. TWO GH DOSES IN THE TREATMENT OF TURNER'S STNDROHE (TS) PATIENTS: THE HIGHER DOSE INCREASED THE GROWTH VELOCITY ONLY IN PATIENTS OVER 7 YEARS OLD. Pediatr Res 33 (Suppl 5), S39 (1993). https://doi.org/10.1203/00006450-199305001-00213
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00213